AVRO AVROBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVRO

Price (delayed)

$1.28

Market cap

$56.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

-$45.22M

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy ...

Highlights
The EPS has grown by 13% year-on-year and by 8% since the previous quarter
AVRO's net income is up by 8% year-on-year and by 8% since the previous quarter
AVROBIO's equity has decreased by 49% YoY and by 17% from the previous quarter
AVROBIO's quick ratio has decreased by 31% from the previous quarter and by 19% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.avrobio.com
Peers: OVID

Key stats

What are the main financial stats of AVRO
Market
Shares outstanding
43.77M
Market cap
$56.03M
Enterprise value
-$45.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$108.76M
EBITDA
-$107.22M
Free cash flow
-$100.55M
Per share
EPS
-$2.49
Free cash flow per share
-$2.3
Book value per share
$2.24
Revenue per share
$0
TBVPS
$2.96
Balance sheet
Total assets
$129.5M
Total liabilities
$31.41M
Debt
$15.21M
Equity
$98.09M
Working capital
$110.04M
Liquidity
Debt to equity
0.16
Current ratio
7.8
Quick ratio
7.19
Net debt/EBITDA
0.94
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-66.6%
Return on equity
-82.5%
Return on invested capital
-894.8%
Return on capital employed
-96%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVRO stock price

How has the AVROBIO stock price performed over time
Intraday
-1.54%
1 week
4.07%
1 month
-20.5%
1 year
-20.99%
YTD
79.55%
QTD
79.55%

Financial performance

How have AVROBIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$108.14M
Net income
-$109.08M
Gross margin
N/A
Net margin
N/A
AVRO's operating income is up by 9% year-on-year and by 8% since the previous quarter
AVRO's net income is up by 8% year-on-year and by 8% since the previous quarter

Growth

What is AVROBIO's growth rate over time

Valuation

What is AVROBIO stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 13% year-on-year and by 8% since the previous quarter
AVRO's price to book (P/B) is 79% less than its 5-year quarterly average of 2.7 but 16% more than its last 4 quarters average of 0.5
AVROBIO's equity has decreased by 49% YoY and by 17% from the previous quarter

Efficiency

How efficient is AVROBIO business performance
AVROBIO's ROE has plunged by 56% YoY and by 9% from the previous quarter
The ROIC has increased by 46% from the previous quarter
The return on assets has declined by 36% year-on-year and by 4.1% since the previous quarter

Dividends

What is AVRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVRO.

Financial health

How did AVROBIO financials performed over time
The total assets has declined by 40% year-on-year and by 11% since the previous quarter
The total liabilities rose by 37% YoY and by 13% QoQ
AVRO's debt is 84% smaller than its equity
AVROBIO's equity has decreased by 49% YoY and by 17% from the previous quarter
The debt to equity has increased by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.